Arrowhead Pharmaceuticals Inc.
ARWR | NASDAQ
$71.67
+$2.88 (+4.19%)
Sep 22, 2026, 2:11 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Sep 29, 2025 | FY 2024 Sep 29, 2024 | FY 2023 Sep 29, 2023 | FY 2022 Sep 29, 2022 | FY 2021 Sep 29, 2021 | FY 2020 Sep 29, 2020 |
|---|---|---|---|---|---|---|
Revenue | 829.45M | 3.55M | 240.74M | 243.23M | 138.29M | 87.99M |
Cost of Revenue | n/a | 18.6M | 12.49M | 10.42M | n/a | n/a |
Gross Profit | 829.45M | -15.04M | 228.24M | 232.81M | 138.29M | n/a |
Operating Income | 98.35M | -601.08M | -205M | -178.51M | -149.04M | -93.16M |
Interest Income | 37.29M | 22.72M | 15.3M | 5.03M | 6.12M | 9.19M |
Pretax Income | 51.53M | -612.46M | -206.49M | -172.71M | -140.85M | -84.55M |
Net Income | -1.63M | -599.49M | -205.28M | -176.06M | -140.85M | -84.55M |
Selling & General & Admin | 121.92M | 96.82M | 90.93M | 124.43M | 80.98M | 52.28M |
Research & Development | 607.16M | 489.22M | 342.31M | 288.5M | 206.34M | 123.54M |
Other Expenses | 2.03M | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 731.1M | 586.04M | 433.24M | 411.32M | 287.32M | 175.21M |
Interest Expense | 89.36M | 32.35M | 18.33M | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 731.1M | 604.63M | 445.74M | 421.74M | 287.32M | 181.15M |
Income Tax Expense | 21.42M | -2.77M | 2.78M | 3.79M | 2K | 2K |
Shares Outstanding (Basic) | 133.76M | 119.78M | 107.31M | 105.43M | 103.75M | 100.72M |
Shares Outstanding (Diluted) | 133.76M | 119.78M | 106.75M | 105.43M | 103.75M | 100.72M |
EPS (Basic) | -0.01 | -5 | -1.91 | -1.67 | -1.36 | -0.84 |
EPS (Diluted) | -0.01 | -5 | -1.92 | -1.67 | -1.36 | -0.84 |
EBITDA | 164.82M | -561.51M | -175.67M | -162.29M | -132.58M | -87.22M |
EBIT | 140.89M | -580.11M | -188.17M | -172.71M | -140.85M | -93.16M |
Depreciation & Amortization | 23.93M | 18.6M | 12.49M | 10.42M | 8.27M | 5.94M |
Add to Watchlist
Select watchlists to add or remove ARWR